Oppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after...
Oppenheimer raises its price target for Questcor Pharma (QCOR +3%) to $69 from $59 after positive commentary from investor meetings. Investors are becoming more comfortable with QCOR's perceived risks, the firm says, and any additional negative reports will result in limited downside volatility. Acthar reimbursement rates remain “extremely strong,” the firm adds.
From other sites
at Nasdaq.com (Apr 9, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs